MXPA05007743A - Farnesil dibenzodiazepinonas, procesos para su produccion y su uso como productos farmaceuticos. - Google Patents

Farnesil dibenzodiazepinonas, procesos para su produccion y su uso como productos farmaceuticos.

Info

Publication number
MXPA05007743A
MXPA05007743A MXPA05007743A MXPA05007743A MXPA05007743A MX PA05007743 A MXPA05007743 A MX PA05007743A MX PA05007743 A MXPA05007743 A MX PA05007743A MX PA05007743 A MXPA05007743 A MX PA05007743A MX PA05007743 A MXPA05007743 A MX PA05007743A
Authority
MX
Mexico
Prior art keywords
eco
pharmaceutically acceptable
novel
pharmaceuticals
relates
Prior art date
Application number
MXPA05007743A
Other languages
English (en)
Inventor
O Bachmann Brian
Original Assignee
Ecopia Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ecopia Biosciences Inc filed Critical Ecopia Biosciences Inc
Publication of MXPA05007743A publication Critical patent/MXPA05007743A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/38—[b, e]- or [b, f]-condensed with six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10—Nitrogen as only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/29—Micromonospora
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Esta invencion se relaciona con una farnesil dibenzodiazepinona novedosa, llamada ECO-04601, sus sales y derivados farmaceuticamente aceptables, y con metodos para obtener estos compuestos. Un metodo para obtener el compuesto ECO-04601 es mediante el cultivo de una cepa novedosa de Micromonospora sp., 046-ECO11; otro metodo implica la expresion de genes de ruta biosintetica en celulas hospederas transformadas. La presente invencion ademas se relaciona con la cepa 046-ECO11 de Micromonospora sp., con el uso del compuesto ECO-04601 y sus sales y derivados farmaceuticamente aceptables como productos farmaceuticos, en particular con su uso como inhibidores del crecimiento de celulas cancerigenas, crecimiento de celulas bacterianas, lipoxigenasa de mamiferos, y con composiciones farmaceuticas que comprenden el compuesto ECO-04601 o una sal farmaceuticamente aceptable o derivado del mismo. Por ultimo, la invencion se relaciona con secuencias polinucleotidas novedosas y sus proteinas codificas, que estan involucradas en la biosintesis del compuesto ECO-04601.
MXPA05007743A 2003-01-21 2004-01-21 Farnesil dibenzodiazepinonas, procesos para su produccion y su uso como productos farmaceuticos. MXPA05007743A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US44112603P 2003-01-21 2003-01-21
US49299703P 2003-08-07 2003-08-07
US51828603P 2003-11-10 2003-11-10
PCT/CA2004/000069 WO2004065591A1 (en) 2003-01-21 2004-01-21 Farnesyl dibenzodiazepinones, processes for their production and their use as pharmaceuticals

Publications (1)

Publication Number Publication Date
MXPA05007743A true MXPA05007743A (es) 2005-11-04

Family

ID=32777010

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05007743A MXPA05007743A (es) 2003-01-21 2004-01-21 Farnesil dibenzodiazepinonas, procesos para su produccion y su uso como productos farmaceuticos.

Country Status (9)

Country Link
US (6) US7101872B2 (es)
EP (1) EP1585814B1 (es)
JP (1) JP4913588B2 (es)
AU (1) AU2004206046B2 (es)
CA (1) CA2466340C (es)
ES (1) ES2483897T3 (es)
MX (1) MXPA05007743A (es)
NZ (2) NZ541815A (es)
WO (1) WO2004065591A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7297524B2 (en) * 2003-01-21 2007-11-20 Thallion Pharmceuticals Inc. Polynucleotides for production of farnesyl dibenzodiazepinones
AU2004206046B2 (en) * 2003-01-21 2009-12-17 Thallion Pharmaceuticals Inc. Farnesyl dibenzodiazepinones, processes for their production and their use as pharmaceuticals
US7186713B2 (en) * 2003-01-21 2007-03-06 Ecopia Biosciences, Inc. Farnesyl dibenzodiazepinones and methods of treating cancer using same
WO2006034574A1 (en) * 2004-09-27 2006-04-06 Ecopia Biosciences Inc. Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals
EP1733758A1 (en) * 2005-05-16 2006-12-20 Ecopia Biosciences Inc. Methods for administration of a farnesyl dibenzodiazepinone
US7763604B2 (en) 2005-05-16 2010-07-27 Thallion Pharma Ceuticals, Inc. Methods for administration of a farnesyl dibenzodiazepinone
AU2006254675A1 (en) * 2005-06-02 2006-12-07 Thallion Pharmaceuticals Inc. Formulation comprising farnesyl dibenzodiazepinone and a pharmaceutically acceptable surfactant
EP1983997A4 (en) * 2006-01-31 2009-06-17 Thallion Pharmaceuticals Inc CRYSTALLINE FORMS OF A FARNESYL DIBENZODIAZEPINONE
CA2585058A1 (en) * 2006-04-14 2007-10-14 Thallion Pharmaceuticals Inc. Process for producing farnesylated dibenzodiazepinone by fermentation
EP2131657A1 (en) * 2007-02-28 2009-12-16 Merck & Co., Inc. Substituted benzodiazepinones, benzoxazepinones and benzothiazepinones as sodium channel blockers
US20090170837A1 (en) * 2007-08-17 2009-07-02 Thallion Pharmaceuticals Inc. Methods for treating ras driven cancer in a subject
US20090062255A1 (en) * 2007-08-17 2009-03-05 Thallion Pharmaceuticals Inc. Tumor-targeting evaluation methodology and compounds related thereto
CN103764668B (zh) * 2011-07-09 2016-08-17 加利福尼亚大学董事会 白血病干细胞靶向配体及应用方法
CA3084457A1 (en) * 2017-10-27 2019-05-02 Amo Pharma Ltd. Methods of treating phelan mcdermid syndrome using farnesyl dibenzodiazepinones
US11649218B2 (en) * 2018-03-09 2023-05-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same
CN109504689B (zh) * 2019-01-16 2021-09-17 河南省商业科学研究所有限责任公司 参与调控链霉菌中act产量的转运蛋白编码基因
KR102087786B1 (ko) * 2019-08-19 2020-03-12 국립낙동강생물자원관 항균 및 항암 기능을 가지는 물옥잠 분리 마이크로모노스포라 속 m2 균주 및 이의 용도
WO2021243171A1 (en) * 2020-05-29 2021-12-02 Amo Pharma Ltd Methods of synthesizing farnesyl dibenzodiazepinones
EP4473970A4 (en) 2022-03-31 2026-01-21 Eisai R&D Man Co Ltd PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TUMORS
WO2024168152A1 (en) * 2023-02-08 2024-08-15 The Research Foundation For The State University Of New York Benzodiazepinone-derived inhibitors of egfr and her2
AU2023439518A1 (en) 2023-04-06 2025-08-28 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5039660A (en) 1988-03-02 1991-08-13 Endocon, Inc. Partially fused peptide pellet
EP0354727A3 (en) 1988-08-08 1990-11-22 Eli Lilly And Company Novel single stranded phasmid vectors and methods for transforming streptomyces and other actinomycetes
US5283173A (en) * 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
EP0618972A1 (en) 1991-12-16 1994-10-12 E.I. Du Pont De Nemours And Company CONSTITUTIVE EXPRESSION OF P450SOY AND FERREDOXIN-SOY IN $i(STREPTOMYCES), AND BIOTRANSFORMATION OF CHEMICALS BY RECOMBINANT ORGANISMS
PT759774E (pt) 1993-09-22 2002-11-29 Xoma Technology Ltd Metodo para o tratamento de infeccoes bacterianas gram-negativas por administracao de um produto de proteina bactericida indutora da permeabilidade (bip) e de um antibiotico
US5556772A (en) 1993-12-08 1996-09-17 Stratagene Polymerase compositions and uses thereof
ATE219684T1 (de) 1994-01-14 2002-07-15 Xoma Technology Ltd Anti gram positive bakterielle verfahren und mittel
US5541181A (en) * 1994-05-26 1996-07-30 Bristol-Myers Squibb Company Compound produced by a strain of micromonospora
US5561122A (en) * 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
US5830695A (en) 1995-11-29 1998-11-03 Sankto Company, Limited Actinomycete promoter
US6333322B1 (en) 1996-03-13 2001-12-25 Eisai Co., Ltd. Nitrogen-containing tricyclic compounds and drugs containing the same
US7257562B2 (en) * 2000-10-13 2007-08-14 Thallion Pharmaceuticals Inc. High throughput method for discovery of gene clusters
DE60228439D1 (de) * 2001-06-06 2008-10-02 Dsm Ip Assets Bv Verbesserte isoprenoid herstellung
CA2352451C (en) * 2001-07-24 2003-04-08 Ecopia Biosciences Inc. High throughput method for discovery of gene clusters
US6683300B2 (en) * 2001-09-17 2004-01-27 Science & Engineering Services, Inc. Method and apparatus for mass spectrometry analysis of common analyte solutions
AU2004206046B2 (en) * 2003-01-21 2009-12-17 Thallion Pharmaceuticals Inc. Farnesyl dibenzodiazepinones, processes for their production and their use as pharmaceuticals

Also Published As

Publication number Publication date
AU2004206046B2 (en) 2009-12-17
US20060079509A1 (en) 2006-04-13
US7521222B2 (en) 2009-04-21
CA2466340C (en) 2007-07-10
US7304054B2 (en) 2007-12-04
WO2004065591A1 (en) 2004-08-05
US20060079512A1 (en) 2006-04-13
AU2004206046A1 (en) 2004-08-05
US20080131943A1 (en) 2008-06-05
NZ541815A (en) 2008-07-31
NZ561169A (en) 2008-06-30
US20090263886A1 (en) 2009-10-22
JP4913588B2 (ja) 2012-04-11
CA2466340A1 (en) 2004-08-09
ES2483897T3 (es) 2014-08-08
EP1585814A1 (en) 2005-10-19
US20080199940A1 (en) 2008-08-21
EP1585814B1 (en) 2014-05-07
US20050043297A1 (en) 2005-02-24
JP2006515874A (ja) 2006-06-08
US7101872B2 (en) 2006-09-05

Similar Documents

Publication Publication Date Title
MXPA05007743A (es) Farnesil dibenzodiazepinonas, procesos para su produccion y su uso como productos farmaceuticos.
Hong et al. Mycolactones: immunosuppressive and cytotoxic polyketides produced by aquatic mycobacteria
CA2453080A1 (en) Polyene polyketides, processes for their production and their use as a pharmaceutical
Commichau et al. Overexpression of a non-native deoxyxylulose-dependent vitamin B6 pathway in Bacillus subtilis for the production of pyridoxine
EP1537227A4 (en) METHOD FOR EFFECTIVE RNA INTERFERENCE IN SUGAR CELLS
ITMI20101642A1 (it) Processo per la produzione di acido ialuronico in escherichia coli o bacillus subtilis
MX2008011038A (es) Plantas que tienen un rendimiento incrementado y metodo para obtenerlas.
WO2014059275A3 (en) Process for producing gougerotin employing streptomyces microflavus strains
CN101151368A (zh) 基因表达盒及转化体、及使用该转化体的2-脱氧-青蟹肌糖的制备方法及2-脱氧-青蟹肌糖的精制方法
CN104830748A (zh) 一种弱化hemB基因表达提高大肠杆菌合成5-氨基乙酰丙酸的方法
AU2003231284A1 (en) Seed specific usp promoters for expressing genes in plants
NZ591874A (en) Photosynthetic microorganisms enriched in selenium using selenohydroxy acid compounds, uses thereof in nutrition, cosmetics and pharmacy
DE102013209274A1 (de) Mikroorganismus und Verfahren zur fermentativen Überproduktion von Gamma-Glutamylcystein und Derivaten dieses Dipeptids
Kudo et al. Mechanism of S-adenosyl-L-methionine C-methylation by cobalamin-dependent radical S-adenosyl-L-methionine methylase in 1-amino-2-methylcyclopropanecarboxylic acid biosynthesis
Li et al. Enhancement of production of D-glucosamine in Escherichia coli by blocking three pathways involved in the consumption of GlcN and GlcNAc
JP2012125170A (ja) チオール化合物高生産微生物
CN114350585B (zh) 一种高产d-泛酸的基因工程菌、构建方法其应用
Yang et al. Synthesis and activity study of phosphonamidate dipeptides as potential inhibitors of VanX
US20190127313A1 (en) Antimicrobial agents
CN116426454A (zh) 一种提高阿维菌素B1a组分效价和比例的基因工程方法
KR101582259B1 (ko) 이소프렌을 생산하는 대장균 균주 fmis2 및 이의 용도
Kang et al. Toward steadfast growth of antibiotic research in China: From natural products to engineered biosynthesis
Skarbek et al. Synthesis and antimicrobial activity of 6-sulfo-6-deoxy-D-glucosamine and its derivatives
WO2015047202A2 (en) Rhodobacter sphaeroides o.u.oo1 producing 5-aminolevulinic acid with a new metabolic pathway and 5-aminolevulinic acid production method
WO2009054138A1 (ja) コハク酸アミド化合物の製造法

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: THALLION PHARMACEUTICALS INC.*

FG Grant or registration